Ublituximab, an anti-CD20 monoclonal antibody, is the latest DMT to have gained regulatory approval in the United States. The Institute for Clinical and Economic Review (ICER) evaluated ublituximab alongside 4 other monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, and rituximab) and 5 oral therapies (dimethyl fumarate, fingolimod, ozanimod, ponesimod, and teriflunomide) as first-line DMTs for relapsing forms of MS. This report presents the summary of our systematic literature review and cost-effectiveness analysis and highlights the key policy recommendations discussed at the New England Comparative Effectiveness Public Advisory Council (CEPAC) public meeting on January 20, 2023. The detailed report is available at https://icer.org/wp-content/uploads/2022/04/ICER_MS_Final_Evidence_Report_022123.pdf
